ArticleAnnals of medicine2025
Incidence and prevalence of gout in Eastern China from 2011 to 2021: a retrospective population-based study.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Regarding 'incidence and prevalence of gout in Eastern China from 2011 to 2021: a retrospective population-based study'.Annals of medicine · 2026Article
- Association between immune-inflammation index and the risk of gout attack: a systematic review and meta-analysis.Therapeutic advances in musculoskeletal disease · 2026Article
- Assessing the content and quality of gout-related videos on video platforms: A cross-sectional study.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo characterize the burden of gout by estimating the temporal trends in prevalence and incidence, and assessing age- and gender-specific patterns in Yinzhou, Ningbo, China (2011-2021).
methodsA population-based retrospective study was conducted using the Yinzhou Regional Health Information Platform. Poisson regression estimated the 95% confidence intervals (CIs) for prevalence and incidence rates, and relative risks for both rates across subgroups. Age-standardized incidence (ASIR) and prevalence rates (ASPR) were calculated based on China's 2020 census. The average annual percent changes (AAPCs) of standardized rates were calculated to estimate the secular trends using joinpoint regression analysis.
resultsOf the over 1.1 million resident adults, 23,967 gout cases were identified over an eleven-year period. The total incidence and prevalence rates from 2011 to 2021 were 211.29 (95% CI: 208.28-214.33)/100,000 person-years and 2.16% (95% CI: 2.13% to 2.19%), respectively. The incidence and prevalence rates of gout was more than twice as heavy in men than women, and exhibited a rising tendency with advancing age, particularly for elderly men. Additionally, lower education attainment, obesity, and unfavorable lifestyle contributed significantly to the burden of gout. ASIR (AAPC: 5.37, 95% CI: 0.30-10.70) and ASPR (AAPC: 7.75, 95% CI: 6.29-9.23) increased significantly over the 11-year period, though ASIR in women remained stable.
conclusionsThe incidence and prevalence of gout increased over time, showing age- and gender-specific patterns. The healthcare authorities need to focus on the burden of gout and guide targeted prevention and treatment strategies for gout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.